View Item 

Show simple item record

Development and introduction of recombinant factor VIII – a clinician’s experience
dc.contributor.authorLusher, J. M.en_US
dc.date.accessioned2012-07-12T17:22:28Z
dc.date.available2013-09-03T15:38:26Zen_US
dc.date.issued2012-07en_US
dc.identifier.citationLusher, J. M. (2012). "Development and introduction of recombinant factor VIII â a clinicianâ s experience." Haemophilia 18(4). <http://hdl.handle.net/2027.42/92006>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92006
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleDevelopment and introduction of recombinant factor VIII – a clinician’s experienceen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationotherMarion I. Barnhart Chair in Hemostasis Research, Distinguished Professor of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA and Medical Director, Special Coagulation Laboratory, Division of Hematology/Oncology, Children’s Hospital of Michigan Detroit, MI, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92006/1/hae2804.pdf
dc.identifier.doi10.1111/j.1365-2516.2012.02804.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceLusher JM, Scharrer I. Evaluation of recombinant factor VIII safety: Kogenate ® FS/Bayer. Int J Hematol 2009; 90: 446 – 54.en_US
dc.identifier.citedreferenceAddiego JE, Kasper CK, Abildgaard CF et al. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462 – 4.en_US
dc.identifier.citedreferenceLusher JM. Inhibitors in young boys with haemophilia. Bailliere’s Clin Haematol 2000; 13: 457 – 68.en_US
dc.identifier.citedreferenceWhite GC, DiMichele D, Mertens K et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Thromb Haemost 1999; 81: 462.en_US
dc.identifier.citedreferenceKreuz W, Gill JC, Rothschild C et al. Full‐length sucrose‐formulated recombinant factor FVIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457 – 67.en_US
dc.identifier.citedreferenceBlanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319 – 26.en_US
dc.identifier.citedreferenceMusso R, Santagostino E, Faradji A et al. Safety and efficacy of sucrose‐formulated full‐length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2006; 99: 52 – 8.en_US
dc.identifier.citedreferenceSandberg H, Almstedt A, Braudt J. Structural and funcitonal characteristics of a B‐domain deleted recombinant factor VIII molecule, r‐VIII SQ. Thromb Haemost 2001; 85: 93 – 100.en_US
dc.identifier.citedreferenceMikaelsson M, Eriksson B, Lind P et al. Manufacturing and characterization of a new B‐domain deleted recombinant factor VIII, r‐VIII SQ. Thromb Haemost 1993; 69: 1205. Abstract No. 2359.en_US
dc.identifier.citedreferenceLusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38 – 49.en_US
dc.identifier.citedreferenceCourter SG, Bedrosian CL. Clinical evaluation of B‐domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38 ( Suppl. 4 ): 44 – 51.en_US
dc.identifier.citedreferenceRecht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctogoc alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy and pharmacokinetic equivalence to full‐length recombinant FVIII. Haemophilia 2009; 15: 869 – 80.en_US
dc.identifier.citedreferenceScharrer I, Bray GL, Neurtzling O. Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates. Haemophilia 1999; 5: 145 – 54.en_US
dc.identifier.citedreferenceScharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma‐derived to recombinant factor VIII. Haemophilia 2001; 7: 346 – 8.en_US
dc.identifier.citedreferenceLusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2: 863 – 5.en_US
dc.identifier.citedreferencePool JG, Shannon AE. Production of high‐potency concentrates of antihemophilic globulin in a closed‐bag system. N Engl J Med 1965; 273: 1443 – 7.en_US
dc.identifier.citedreferenceWebster WP, Roberts HR, Thelin GM, Wagner RH, Brinkhous KM. Clinical use of a new glycine‐precipitated antihemophilic fraction. Am J Med Sci 1965; 250: 643 – 51.en_US
dc.identifier.citedreferenceEvatt BL, Gomperts ED, McDougal JS, Ramsey RB. Coincidental appeartance of LAV/HTLV‐III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312: 483 – 6.en_US
dc.identifier.citedreferenceJohnson RE, Lawrence DN, Evatt BL et al. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. Am J Epidemiol 1985; 121: 797 – 810.en_US
dc.identifier.citedreferencePierce GF, Lusher JM, Brownstein AP, Goldsmith JC, Kessler CM. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost and supply on therapy. JAMA 1989; 261: 3434 – 8.en_US
dc.identifier.citedreferenceNational Hemophilia Foundation Medical and Scientific Advisory Council (MASAC) Recommendation concerning the treatment of hemophilia and related bleeding disorders. Medical Advisory No. 301. New York: National Hemophilia Foundation, 1997.en_US
dc.identifier.citedreferenceBerntorp E. A systematic overview of the first pasteurized vWF/FVIII medicinal product, Haemate ®‐ P/Humate ® ‐P: history and clinical performance. Eur J Haematol 2008; 80 ( Suppl. 70 ): 3 – 35.en_US
dc.identifier.citedreferenceLusher JM, Salzman PM, The Monoclate Study Group. Viral safety and inhibitor development associated with factor VIII C ultra‐purified from plasma in hemophiliacs previously unexposed to factor VIII C concentrates. Semin in Hematol 1990; 27 ( Suppl. 2 ): 1 – 7.en_US
dc.identifier.citedreferenceLusher JM. Viral safety and inhibitor development associated with monoclonal antibody‐purified FVIII C. Ann Hematol 1991; 63: 138 – 41.en_US
dc.identifier.citedreferenceBrettler DB, Forsberg AD, Levine PH. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 59 – 63.en_US
dc.identifier.citedreferencePiszkiewicz D, Sun CS, Tondreau SC. Inactivation and removal of human immunodeficiency virus in monoclonal antibody purified antihemophilic factor (human) (Hemofil M). Thromb Res 1989; 55: 627 – 34.en_US
dc.identifier.citedreferenceGitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326 – 30.en_US
dc.identifier.citedreferenceWood WI, Capon DJ, Simonsen CC et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330 – 7.en_US
dc.identifier.citedreferenceVehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 337 – 42.en_US
dc.identifier.citedreferenceToole JT, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihemophilic factor. Nature 1984; 312: 342 – 7.en_US
dc.identifier.citedreferenceWhite GC, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166 – 70.en_US
dc.identifier.citedreferenceWhite GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660 – 7.en_US
dc.identifier.citedreferenceSchwartz RSS, Abildgaard CF, Aledort LM et al. Human recombinant DNA‐derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800 – 5.en_US
dc.identifier.citedreferenceLusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453 – 9.en_US
dc.identifier.citedreferenceBray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428 – 35.en_US
dc.identifier.citedreferenceGruppo R, Chen H, Schroth P, Bray GL. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients: a 7.3 year update. Haemophilia 1998; 4: 228.(Abstract # 291, XXIII Congress of the WFH, The Hague).en_US
dc.identifier.citedreferenceLusher JM. Summary of clinical experience with recombinant factor VIII products – Kogenate. Ann Hematol 1994; 68: S3 – 6.en_US
dc.identifier.citedreferenceLusher JM. Recombinant clotting factor concentrates. Bailliere’s Clin Haematol 1996; 9: 291 – 303.en_US
dc.identifier.citedreferenceLusher J, Abildgaard C, Arkin S et al. Human recombinant DNA‐derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574 – 83.en_US
dc.identifier.citedreferenceEhrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae2804.pdf
Size:
51.51KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.